Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows
12:30pm, Thursday, 01'st Aug 2024
The active ingredient in Eli Lilly's (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Thursday, 01'st Aug 2024
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly Finds Another Condition for Zepbound to Treat. The Stock Is Up.
10:29am, Thursday, 01'st Aug 2024
The drug appears to have hit a home run treating a common form of heart failure.
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lill
Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study
08:01am, Thursday, 01'st Aug 2024
Eli Lilly's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data. The findings add to mounting evidence that Zepbou
What You Need to Know Ahead of Eli Lilly Earnings
07:41am, Thursday, 01'st Aug 2024
Eli Lilly (LLY) reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs Mounjaro and Zepbound.
Lilly says weight loss drug cut heart failure risk by 38% in trial
06:48am, Thursday, 01'st Aug 2024
Trial results show Eli Lilly's weight loss drug Zepbound reduces the risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure, the company said on Thursda
Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization , oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepat
Japan health ministry panel backs Eli Lilly dementia drug donanemab
06:08am, Thursday, 01'st Aug 2024
A Japanese health ministry panel on Thursday recommended approval for Eli Lilly's dementia treatment donanemab.
Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
12:24pm, Wednesday, 31'st Jul 2024
Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Denifanstat is progressing toward Phase 3 trials, with positive res
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
10:06am, Wednesday, 31'st Jul 2024
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
07:00am, Wednesday, 31'st Jul 2024
One of the most pertinent drivers of the stock market that is often not considered by many investors is the demographic trajectory of the U.S. Currently, the U.S. population is older than ever before
3 Biotech Stocks That Could Make Your Summer Unforgettable
03:07pm, Tuesday, 30'th Jul 2024
If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ: GPCR ), for example.
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly
